GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Claritev Corp (NYSE:CTEV) » Definitions » 3-Year RORE %

CTEV (Claritev) 3-Year RORE % : 45.72% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Claritev 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Claritev's 3-Year RORE % for the quarter that ended in Dec. 2024 was 45.72%.

The industry rank for Claritev's 3-Year RORE % or its related term are showing as below:

CTEV's 3-Year RORE % is ranked better than
83.93% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: -0.57 vs CTEV: 45.72

Claritev 3-Year RORE % Historical Data

The historical data trend for Claritev's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Claritev 3-Year RORE % Chart

Claritev Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
3-Year RORE %
Get a 7-Day Free Trial - - 40.87 34.49 45.72

Claritev Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.49 63.61 78.90 76.08 45.72

Competitive Comparison of Claritev's 3-Year RORE %

For the Health Information Services subindustry, Claritev's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Claritev's 3-Year RORE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Claritev's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Claritev's 3-Year RORE % falls into.



Claritev 3-Year RORE % Calculation

Claritev's 3-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -101.54--36 )/( -143.357-0 )
=-65.54/-143.357
=45.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 3-year before.


Claritev  (NYSE:CTEV) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Claritev 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Claritev's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Claritev Business Description

Traded in Other Exchanges
N/A
Address
7900 Tysons One Place, Suite 400, McLean, VA, USA, 22102
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Executives
Michael Kim officer: See Remarks POLARIS PARENT CORP, 115 FIFTH AVENUE, NEW YORK NY 10003
Anthony Jr Colaluca director MULTIPLAN CORPORATION, 115 FIFTH AVENUE, NEW YORK NY 10003
John Michael Prince director 115 FIFTH AVE., NEW YORK NY 10003
Nutter Carol officer: SVP, Chief People Officer 115 FIFTH AVE., NEW YORK NY 10003
Mark Tabak director, officer: Chief Executive Officer 115 FIFTH AVENUE, NEW YORK NY 10003
Michael K. Attal director 425 PARK AVENUE, 30TH FLOOR, NEW YORK NY 10022
James M Head officer: EVP & Chief Financial Officer 3001 COLORADO BLVD, DENTON TX 76210
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
C Martin Harris director
H&f Corporate Investors Viii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
Music Investments Gp, Llc 10 percent owner C/O HELLMAN & FRIEDMAN, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Music Investments, L.p. 10 percent owner C/O HELLMAN & FRIEDMAN, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Glenn R August director C/O OHA - 1114 AVENUE OF THE AMERICAS, 27TH FLOOR, NEW YORK NY 10036
Paul Galant officer: President, New Markets 88 WEST PLUMERIA DRIVE, SAN JOSE CA 95134
Michael Stuart Klein director, 10 percent owner, officer: Chief Executive Officer C/O DAVIS POLK & WARDWELL, 450 LEXINGTON AVENUE, NEW YORK NY 10017